Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) CEO Mark James Litton sold 4,820 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $2.91, for a total value of $14,026.20. Following the sale, the chief executive officer now directly owns 144,397 […]
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) Director Perceptive Advisors Llc purchased 32,134 shares of the stock in a transaction on Wednesday, December 27th. The shares were purchased at an average cost of $2.28 per share, with a total value of $73,265.52. Following the transaction, the director now owns 4,829,412 shares of the company’s […]
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 741,900 shares, a decline of 7.6% from the September 15th total of 803,300 shares. Based on an average trading volume of 145,700 shares, […]
Tang Capital Management LLC acquired a new stake in Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 485,234 shares of the company’s stock, valued at approximately $1,538,000. A number of other institutional investors also recently bought and […]
Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) insider Andrew Gengos bought 45,000 shares of Athira Pharma stock in a transaction dated Monday, June 5th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $135,000.00. Following the completion of the transaction, the insider now owns 65,012 shares of […]